Live Breaking News & Updates on Daniel Vaena

Stay updated with breaking news from Daniel vaena. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Experts Discuss Current Standards, Selection, and Uncertainties in Bladder and Renal Cancer Care

Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches. ....

Vanderbilt University , United States , University Of Tennessee , Nikhil Gopal , Daniel Vaena , Enfortumab Vedotin , Bradleyg Somer , Kathryne Beckermann , Holgerl Gieschen , Division Of Hematology , Department Of Urology , University Of Tennessee Health Science Center , Department Of Medicine , Cancer Center Research Institute , Cancer Council , College Of Medicine , Vanderbilt University Medical Center , European Society For Medical Oncology Annual Meeting , Onclive State , Science Summit , West Cancer Center , Research Institute , Executive Cancer Council , Vanderbilt University Medical , Tennessee Health Science , Genitourinary Oncology ,

Belzutifan Regimens Show Promise in RCC as Frontline IO/TKI Armamentarium Expands

Nikhil A. Gopal, MD, discusses the benefit of belzutifan in addition to effective immunotherapy-based regimens in advanced RCC. ....

United States , University Of Tennessee , Nikhila Gopal , Daniel Vaena , University Of Tennessee Health Science Center , Department Of Urology , College Of Medicine , Science Summit , Tennessee Health Science Center ,

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting
Font : A-A+
Data show ongoing durable responses beyond one year in monotherapy and in combination with Opdivo® in heavily pre-treated patients including one patient with prior progression on Opdivo®
HOLON, Israel, June 8, 2021 /PRNewswire/ Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab) in an oral presentation at the ASCO 2021 Annual Meeting, being held virtually on June 4-8, 2021. COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered computationally by Compugen. ....

Tel Aviv , Daniel Vaena , Compugen Ltd , Corporate Communications Compugen Ltd , Exchange Commission , Securities Exchange , Tel Aviv Stock Exchange , John Mullaly Lifesci Advisors , Cancer Center Research Institute , Prnewswire Compugen Ltd , Anat Cohen Dayag , Experimental Therapeutics Program , West Cancer Center Research Institute , South San Francisco , Looking Statement , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Annual Report , Yvonne Naughton Phd Head , Investor Relations , Corporate Communications Compugen , Ealth Press Release , தொலைபேசி அவிவ் , பரிமாற்றம் தரகு , பத்திரங்கள் பரிமாற்றம் ,